9th National Cancer Research Institute Cancer Conference 2013
03 November 2013 - 06 November 2013
-Be part of the leading cancer research meeting in the UK
-Benefit from a pioneering programme, with high-quality data
-Enjoy the multidisciplinary approach to cancer research: from baisc research to prevention, diagnosis, treatment and survivorship
Liverpool, UK
http://conference.ncri.org.uk/
Alzheimer’s Disease Summit: The Path to 2025
06 November 2013 - 07 November 2013
To help drive progress on Alzheimer’s research and development over the next decade, the New York Academy of Sciences is partnering with the Global CEO Initiative on Alzheimer’s Disease (CEOi) and the U.S. National Institute on Aging/NIH to convene a new biennial summit, “Path to 2025.” Organized by a diverse group of partners, the inaugural summit will be held November 6-7, 2013 in New York. The meeting is expected to bring together more than 60 leaders in Alzheimer’s disease across sectors, representing more than eight countries.
The New York Academy of Sciences, New York, NY, USA
http://www.nyas.org/Events/Detail.aspx?cid=a643a4ab-37b7-42f3-b0c9-c5e88909c9b4
3rd Cancer Epigenetics
06 November 2013 - 08 November 2013
GTC’s 3rd Cancer Epigenetics Conference, one of two parallel tracks of the 2nd Cancer Summit – Novel Approaches to Drug Discovery on November 6-8 in San Francisco, CA, is the only cancer epigenetics conference that brings together leading experts from the industry and academia to collaborate on the latest cutting edge research on novel mechanisms, therapeutics, drug discovery, developments, biomarkers and diagnostics for cancer epigenetics.
San Francisco, CA, USA
http://www.gtcbio.com/conference/cancer-epigenetics-overview
8th Cell Based Assay & Screening Technologies Conference
06 November 2013 - 08 November 2013
Join us as we discuss these questions and explore how the field will move forward into the future. This meeting will connect industry leaders from major pharmaceutical companies, cutting-edge biotech companies and top researchers from academia and government to present innovative and relevant applications of current assay technologies to continually improve efficacy and meaningful data output and discuss the potential of novel analytical and screening technologies in drug discovery and development.
Sheraton Fisherman's Wharf Hotel, San Francisco, CA, USA
http://www.gtcbio.com/conference/assay-overview
The synaptic basis of neurodegenerative disorders
07 November 2013 - 08 November 2013
There is increasing evidence that neurodegenerative diseases have at their basis dysfunctions in the receptors and ion channels subserving synaptic communication. This would explain the cognitive decline and neurological and motor symptoms associated with a host of chronic disorders such as Alzheimer’s, Parkinson’s and Huntington’s diseases.
Understanding the cellular and molecular events underpinning such synaptic dysfunction is a key goal if we are to halt or even reverse the inexorable deterioration currently observed in these conditions. Accordingly, much insight has already been gleaned on the genetics, protein misfolding, cell death pathways and mitochondrial involvement in chronic neurodegenerative diseases. From this insight has come greater knowledge of the fundamentals of synaptic function, but more so an appreciation of the potential, not only for drug-based therapies, but also biological treatments, for example via stem cells.
This conference will bring together world experts addressing the very mechanisms of neurodegeneration and the prospects for treatments that such knowledge promises.
Sheraton San Diego Hotel and Marina, San Diego, CA, USA
http://www.neuropharmacology-conference.elsevier.com/index.html
European Antibody Congress 2013
11 November 2013 - 13 November 2013
European Antibody Congress 2013 is a proven conference and exhibition bringing together buyers and sellers from across the mAb and next generation technology industry.
Having helped over 2000 antibody players in its 8 year history, we can safely say this event is where science meets business.
Starling Geneva Hotel & Conference Center, Geneva, Switzerland
http://www.terrapinn.com/2013/european-antibody-congress/index.stm
2nd Annual World Drug Repositioning Congress
14 November 2013 - 15 November 2013
World Drug Repositioning Congress Europe 2013 is the region’s only market place for drug development, indication expansion and lifecycle extension stakeholders: an exhibition, a strategic keynote conference and real life case studies.
World Drug Repositioning Congress is where innovation and expertise are showcased, solutions are found and the means to exploit one of the fastest growing industry sectors are discovered.
World Drug Repositioning Congress has a proven track record of introducing buyers to sellers. The event is where solution and service providers grow their business and stand out from the crowd.
Starling Geneva Hotel & Conference Centre, Geneva, Switzerland
http://www.terrapinn.com/2013/drug-repositioning-europe/attend.stm
Clinical Trials in CNS
18 November 2013 - 19 November 2013
The highly anticipated and respected 12th annual Clinical Trials in CNS Conference returns to London with a two day content packed agenda featuring new approaches taken in this field towards a number of neurodegenerative disorders, from clinical trial modelling and simulation to the role of biomarkers, the agenda presents a detailed look into many aspects of drug discovery and delivery of CNS therapeutics. This innovative conference will give delegates an opportunity to gain insights through case studies and interactive discussion into the best practices in clinical trials.
Marriott Hotel, Regents Park, London
http://www.smi-online.co.uk/goto/clinicaltrialscns37.asp
Cell Based Assays
18 November 2013 - 19 November 2013
Highly accurate in-vitro practices are becoming absolutely vital as is looking at cost-effective assay development. Cell based assays now play an important role into the research pipeline, making a large percentage of total research time and is set to show considerable growth over the coming years.
There are currently 15 FDA approved kinase inhibitor drugs, but there currently remains a huge uncapped potential with these drugs as over 90% of the kinome is unknown. Novel assays have identified kinase targets, improved the function of kinase inhibitors and led to an acceleration in drug discovery with new inhibitor classes.
Marriott Hotel, Regents Park, London, UK
http://www.smi-online.co.uk/pharmaceuticals/uk/conference/cell-based-assays
Clinical Trials in CNS
18 November 2013 - 19 November 2013
With an ever increasing average life expectancy, neurodegenerative diseases are increasingly becoming more prevalent in society. With this comes a need for new and improved therapies for treating these neurodegenerative conditions. From Alzheimer's to Parkinson's disease, the target and mechanism by which a disease manifests itself presents unique challenges in how to approach such treatments not to mention ethical and legal issues behind treatment and trial design.
Marriott Regents Park Hotel, London, UK
http://www.smi-online.co.uk/pharmaceuticals/uk/conference/clinical-trials-in-cns
2013 Barcelona Conference on Epigenetics and Cancer
21 November 2013 - 22 November 2013
As a joint venture of five leading Barcelona institutes, the Barcelona Conferences of Epigenetics and Cancer (BCEC) series has been launched to bring together leading investigators in the fields of chromatin research and cancer. We will discuss fundamental aspects of cancer biology and epigenetics and the possibilities to exploit this knowledge for the development of novel tools for the management of cancer.
The first of the BCEC series in November 2013 will focus on discussing in breadth and depth the current challenges, opportunities and perspectives of cancer epigenetics. More specialized topics will ensue in subsequent years.
CosmoCaixa, Barcelona
http://www.imppc.org/congress/bcec1/index.html